Medicus Pharma (NASDAQ:MDCX) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Medicus Pharma (NASDAQ:MDCX) announced its quarterly earnings results on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07), Zacks reports.

Medicus Pharma Stock Down 4.3%

NASDAQ:MDCX traded down $0.01 on Wednesday, hitting $0.33. The stock had a trading volume of 1,099,044 shares, compared to its average volume of 3,489,210. The stock has a market cap of $18.76 million, a price-to-earnings ratio of -0.12 and a beta of 0.12. The business’s 50-day simple moving average is $0.37 and its two-hundred day simple moving average is $0.55. Medicus Pharma has a 52-week low of $0.25 and a 52-week high of $3.05.

Analysts Set New Price Targets

Several research firms recently commented on MDCX. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Medicus Pharma in a report on Monday, April 20th. Roth Capital began coverage on shares of Medicus Pharma in a report on Tuesday, April 21st. They set a “buy” rating on the stock. Alliance Global Partners started coverage on shares of Medicus Pharma in a report on Tuesday, July 28th. They set a “buy” rating for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Medicus Pharma in a research report on Wednesday, July 8th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $9.00.

Hedge Funds Weigh In On Medicus Pharma

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC bought a new stake in Medicus Pharma during the second quarter valued at approximately $41,000. Osaic Holdings Inc. increased its holdings in Medicus Pharma by 180.0% during the second quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after buying an additional 9,000 shares during the last quarter. Private Advisor Group LLC raised its position in Medicus Pharma by 3.8% in the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock worth $351,000 after acquiring an additional 5,500 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Medicus Pharma during the 3rd quarter worth $59,000. Finally, Commonwealth Equity Services LLC boosted its stake in shares of Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after acquiring an additional 17,611 shares during the last quarter.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.